Arcturus Therapeutics: Downgrading To "Hold" As CF Program Shifts Population Focus

2026-03-06 16:04:32 ET

The last time I spoke about Arcturus Therapeutics Holdings Inc. ( ARCT ) it was with a Seeking Alpha article entitled " Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data ." With respect to this article, I noted that this company was gearing up to release interim results from its LUNAR-CF study using its once-daily inhaled messenger RNA [mRNA] therapeutic candidate ARCT-032 for the treatment of patients with Cystic Fibrosis [CF]. The hope was that this drug would benefit these CF patients who don't respond to currently available CFTR modulatory therapy. Unfortunately, this was not the case, as it was noted in the interim analysis that these patients who received 10 mg ARCT-032 for 28 days did not achieve a clinically meaningful improvement in FEV1....

Read the full article on Seeking Alpha

For further details see: